The discovery of the latest strain of bacteria to hit the medical community are antibiotics resistant bacteria. These bacterial enzymes have the capacity to resist dosages of antibiotics entering the body. The strain is such a worldwide problem that the Prime Minister of UK ordered to study the superbugs back in 2014 and find a cure for it. If left unchecked, there will be more causal deaths than cancer due to these resistant bacteria in the next 35 years.
Researchers from McGill University submitted a paper for publication in the journal "Structure", a detailed investigative study and analysis of bacterial enzymes called kinases. These enzymes strengthen the stains that resist antibiotics treatment. The study and confirmation of these antibiotic resistant bacteria took seven years for the research team until they saw satisfactory evidence of how these strains work.
Researchers began cloning large amounts of these antibiotic resistant bacteria back in 2009. It took them one year after some scientific processes to collect considerable material of these enzymes. The next step is to produce kinase material in a crystalline form similar to that of crystallized sugar. The crystals were then exposed to X-ray radiations at the Canadian Light Source in Saskatchewan.
The process of radiation and analysis took the team another three years of the data obtained from the Saskatchewan Radiation facility, explains Dr. Albert Berghuis, chair of the Department at MacHill University Faculty of Medicine. He further stated that it took another three years to analyze in detail how the antibiotic resistant bacteria resists antibiotics, reports Phys.Org.
The discovery of how these antibiotic-resistant bacteria known as kinases enzymes resists macrolide antibiotics had been established. Two distinct enzymes counteract the healing properties of antibiotics making them antibiotics resistant bacteria. The data on how they resist antibiotics will now allow our scientists to design antibiotics so that kinases will not interact with them reports, High Tech Days.
Dr. Berghuis elaborated that the next step is to improve a more effective macrolide antibiotics, then putting them on trial. To develop these new superbug busters will take another two to three years considering that their seven-year research is only dealt with one facet of the problem. He said that other components should also be considerations for the failure of antibiotics to act on antibiotic resistant bacteria.
